Success for Merck Serono's oral cladribine in pivotal Phase III MS trial
This article was originally published in Scrip
Executive Summary
Merck KGaA's oral formulation of cladribine has met its primary endpoint of a reduction in the relapse rate in patients with the most common form of multiple sclerosis in its first, large two-year Phase III trial. The company plans to file the drug for this use in mid-2009 in both Europe and the US.